My watch list  

26 Current news of Abbott


You can refine your search further. Select from the filter options on the left to narrow down your results.

Abbott Completes Acquisition of STARLIMS Technologies


Abbott announced that it has completed its $123 million acquisition of STARLIMS Technologies Ltd. The acquisition provides Abbott with products and expertise to build its position in laboratory informatics "STARLIMS gives us access to innovative technologies and technical expertise for our ...


Abbott Opens New Research Facility and Pilot Plant in Ludwigshafen


Abbott announced the opening of new development laboratories and a pilot plant facility that will research technologies and test large-scale production of newly developed drug formulations. The expansion is part of Abbott's global drug delivery business, SOLIQS, which is based in ...


Abbott's Acquisition of Kos Pharmaceuticals, Inc. Clears Antitrust Review


Abbott announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to Abbott's offer to purchase all of the outstanding shares of common stock of Kos Pharmaceuticals, Inc. The FTC's ...


Abbott to Invest S$450 Million (US$280 Million) in Largest Nutritional Plant in Singapore

State-of-the-Art Manufacturing Facility to Support Rapidly Growing Demand for Abbott Nutritional Products in Asia


Abbott announced that it is building a nutritional powder manufacturing plant in Singapore's Tuas Biomedical Park 2 at the westernmost tip of the island. The plant is Abbott's first major capital investment in Asia and its largest nutritional investment ever. It is also the largest investment in ...


New Real-Time PCR Test for Chlamydia and Gonorrhea Receives CE Mark Certification


Abbott announced that a highly sensitive new test for the simultaneous detection of the sexually transmitted pathogens Chlamydia trachomatis (CT) and Neissera gonorrhoeae (NG) has received CE Mark certification, allowing it to be marketed in the European Union. The test is designed for use on the ...


Eisai Submits New Drug Application for Rheumatoid Arthritis Drug Adalimumab (D2E7)


Eisai Co., Ltd and Abbott Japan Co., Ltd submitted a new drug application (NDA) to the Minister of Health Labour and Welfare (MHLW) for the manufacturing and marketing for the rheumatoid arthritis drug adalimumab (D2E7), which is co-developed by the two companies in Japan. Adalimumab (D2E7) ...


Abbott named on Top 10 "Best places to work for scientists" by the Scientist Magazine


Abbott was recognized this month for its ability to nurture an environment where scientific talent can flourish by being named No. 8 to The Scientist magazine's "Top 10 Best Places to Work for Scientists" list for the second consecutive year. Abbott was the only company in the Midwest to be named ...


Abbott enters into agreement with Inpeco to expand laboratory automation capabilites


Abbott announced that it has entered into an agreement with Inpeco S.p.A. to expand its laboratory automation capabilities. Through the agreement, Abbott plans to offer a suite of automation solutions that can be customized to address key needs within the laboratory, enhancing the consistency and ...


Abbot Laboratories donates plant to Scotland Development Corporation


Laurinburg, North Carolina, June 27, 2002 — Abbott Laboratories announced that it is donating its Laurinburg, North Carolina plant to the Scotland Development Corporation, a non-profit company that seeks employment opportunities to improve the quality of life for the Scotland County area, ...


Abbott announces plans to acquire full ownership of Hokuriku Seiyaku

Abbott to strengthen presence in world´s second largest health care market


Tokyo, April 22, 2002 — Abbott Laboratories today announced a tender offer in Japan of 38 billion Japanese Yen ($292 million) to acquire the remaining 33.3 percent of the issued common shares of Hokuriku Seiyaku (Tokyo Stock Exchange 4546). In March 2001, Abbott acquired 66.7 percent of the ...


Page 1 From 3
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE